Cohance Lifesciences Ltd vs Ganga Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 18, 2026

Key Highlights

The Latest Trading Price of Cohance Lifesciences Ltd is ₹ 429.5 as of 18 May 15:30 . The P/E Ratio of Cohance Lifesciences Ltd changed from 34.8 on March 2021 to 110.3 on March 2025 . This represents a CAGR of 25.95% over 5 yearsThe P/E Ratio of Ganga Pharmaceuticals Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of Cohance Lifesciences Ltd changed from ₹ 12611 crore on March 2021 to ₹ 29524 crore on March 2025 . This represents a CAGR of 18.55% over 5 yearsThe Market Cap of Ganga Pharmaceuticals Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 years The revenue of Cohance Lifesciences Ltd for the Mar '26 is ₹ 617.28 crore as compare to the Dec '25 revenue of ₹ 550.71 crore. This represent the growth of 12.09% The revenue of Ganga Pharmaceuticals Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Cohance Lifesciences Ltd for the Mar '26 is ₹ 80.33 crore as compare to the Dec '25 ebitda of ₹ 96.65 crore. This represent the decline of -16.89% The ebitda of Ganga Pharmaceuticals Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Cohance Lifesciences Ltd changed from ₹ 75.37 crore to ₹ 8.31 crore over 8 quarters. This represents a CAGR of -66.80% The net profit of Ganga Pharmaceuticals Ltd changed from ₹ 0 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of 0.0% The Dividend Payout of Cohance Lifesciences Ltd changed from 16.5 % on March 2021 to 0 % on March 2025 . This represents a CAGR of -100.00% over 5 yearsThe Dividend Payout of Ganga Pharmaceuticals Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Cohance Lifesciences Ltd

Cohance Lifesciences Limited, formerly known as Suven Pharmaceuticals Limited was incorporated on November 6, 2018.
The name of the Company has been changed to Cohance Lifesciences Limited w.e.f.
May 7, 2025.
Cohance Lifesciences Ltd is an integrated Contract Development and Manufacturing Operations (CDMO) company that serves leading global life science and fine chemical majors.
The Company's comprehensive services encompass- Custom Synthesis, Process R&D, Scale-Up, and Contract Manufacturing of intermediates, APIs, and formulations. Company is engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies.

About Ganga Pharmaceuticals Ltd

Ganga Pharmaceuticals Limited was incorporated as a Public Limited Company in Aug.'94 and promoted by Brij Mohan Sharma.
The Company is engaged in the business of manufacturing & trading in Pharmaceuticals & allied products (Ayurveda). In Apr.'95, the company took over Ganga pharmaceuticals, a proprietary concern (owned by the same promoter), which was manufacturing and marketing ayurvedic products since the last two decades. The company which manufactures ayurvedic medicines, started commercial production in Apr.'95.
In Jul.'96, it came out with a public issue to part-finance the expansion programme involving setting up of a new manufacturing unit for the manufacture of ayurvedic medicines at Murbad, Maharashtra. The company which commenced exports in Jan.'96, has marketing arrangements with parties located in Saudi Arabia, Dubai, Italy, Romania and Russia to market its products in their respective regions.

FAQs for the comparison of Cohance Lifesciences Ltd and Ganga Pharmaceuticals Ltd

Which company has a larger market capitalization, Cohance Lifesciences Ltd or Ganga Pharmaceuticals Ltd?

Market cap of Cohance Lifesciences Ltd is 16,431 Cr while Market cap of Ganga Pharmaceuticals Ltd is 7 Cr

What are the key factors driving the stock performance of Cohance Lifesciences Ltd and Ganga Pharmaceuticals Ltd?

The stock performance of Cohance Lifesciences Ltd and Ganga Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Cohance Lifesciences Ltd and Ganga Pharmaceuticals Ltd?

As of May 18, 2026, the Cohance Lifesciences Ltd stock price is INR ₹429.5. On the other hand, Ganga Pharmaceuticals Ltd stock price is INR ₹12.0.

How do dividend payouts of Cohance Lifesciences Ltd and Ganga Pharmaceuticals Ltd compare?

To compare the dividend payouts of Cohance Lifesciences Ltd and Ganga Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.